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Quality of life (QoL) is increasingly measured in both research and clinical practice. QoL-
assessments are built on a long, empirically-based, and stringent approach. There is ample
evidence that QoL is, in part, heritable. We therefore performed a GWAS relating genetic
variation to QoL in healthy females.
Methods
In 5,142 healthy females, background characteristics (e.g. demographic, clinical, lifestyle
and psychological factors) and QoL by means of the EORTC QLQ-C30 were measured.
Moreover, women were genotyped using a custom array including ~210,000 single nucleo-
tide polymorphisms (SNPs). Initially, SNPs were related to each QoL-domain, by means of
partially adjusted (controlling for age and population stratification) and fully adjusted (con-
trolling for age, population stratification, and background characteristics) regression analy-
ses. Additionally, gene-based analyses were performed relating the combined effect of
SNPs within each gene to QoL using the statistical software package VEGAS.
Results
None of the associations between QoL and genetic variation (i.e. individual SNPs and
genes) reached the bonferroni corrected significance level.
Conclusion
Reasons for a lack of association between genetic markers and QoL could be low variation
in QoL-scores; selecting genetic markers not tagging QoL; or that the genetic effect that
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impacts one’s QoL is mediated through biological pathways rather than the effect of single
SNPs or genes. Therefore, we opt for a pathway-based or system biology approach as a
complementary and powerful approach to analyze the combined effect of genes and their
biological implications in future studies focusing on QoL-issues.
Introduction
Patient-reported outcomes are measurements based on the report that comes directly from the
person, without the amendment or interpretation of others.[1] The most popular and often
used patient-reported outcome is quality of life (QoL). Although many definitions of QoL
exist, there is consensus that it entails at least physical, psychological, and social functioning.
[2] QoL is increasingly measured in both research and clinical practice. QoL-assessments are
built on a long, empirically based stringent approach. In short, QoL-measures are as reliable as
other (clinical) outcomes;[3] have strong prognostic value for mortality and poor health out-
comes;[4–6] and is easily measurable over time[7].
There is ample evidence that a genetic predisposition contributes to one’s QoL.[8] Several
studies describe associations between QoL and the hypothalamic-pituitary-adrenal axis,
immune, neuroendocrine, and cardiovascular systems.[9] In addition, genetic determinants
are well established for depression, well-being, pain, and fatigue.[10–13] Furthermore, family
and twin-studies have shown that the heritability for subjective well-being, depression and anx-
iety ranges from thirty to as much as fifty percent.[11,14,15] Beside genetics, QoL is impacted
by demographic characteristics (e.g. age, sex, and race), lifestyle factors (e.g. diet and smoking),
physical health and psychological factors, such as mood states, and stress.[16–19]
An international and interdisciplinary Consortium for Genetics and Quality of Life Research
(GENEQOL) was instigated in 2009[8] aiming to identify biological mechanisms, genes and
genetic variants involved in QoL. The studies conducted since the start showed that QoL is
related various single nucleotide polymorphisms (SNPs) in cytokine genes and the glutathione
metabolic pathway in various patient groups.[20–22] In a previous study based on healthy
females, we related individual SNPs and the combined effect of SNPs within 139 a priori selected
genes to QoL.[23] We found only one significant relation. Cognitive functioning was associated
with variations in the GSTZ1 gene.[23] For the other genes, no significant association with QoL
was found. A possible explanation for the absence of associations might have been the limited
approach of only including candidate genes. Therefore, we opt for a more agnostic approach in
the present study. Using the same sample of healthy females, a GWAS study was performed relat-
ing genes to QoL. More specifically, the objectives were to (1) relate individual SNPs for each
gene to QoL; and (2) relate the combined effect of SNPs within each gene to QoL.
Methods
Study population and procedure
Data from the Karolinska Mammography Project for Risk Prediction of Breast Cancer
(KARMA) was used. Data used in this manuscript is available upon request through the
KARMA Research Platform which can be found at www.karmastudy.org. Women who attend
mammography screening or a clinical mammography at one of four Swedish participating hos-
pitals are invited to participate in KARMA. In Sweden, the national screening program invites
all women at 18 months intervals for those 40–55 years, and for those aged 56–74 years at 24
months. At each visit women’s blood is donated and processed at the Karolinska biobank.
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Moreover, all women are invited to complete a comprehensive online survey. This survey
addresses breast cancer related issues such as reproductive history, cancer treatment, and fam-
ily history of cancer; lifestyle factors (e.g. alcohol and tobacco use); previous medical conditions
other than breast cancer; medication use; and QoL. The Swedish regional ethical board at the
Karolinska Institutet has approved this study which was conducted in accordance with the
Declaration of Helskini.[24] Women diagnosed with breast cancer before entering KARMA
were excluded from this study. All women gave written consent.
Measurements
Background characteristics. Demographic and clinical factors: Participants reported age,
educational level, the use of common over-the-counter pain killers (e.g. paracetamol and ibu-
profen) and whether they were on hormone replacement therapy (yes/no) during the last year.
Women reported the presence of previous or ongoing medical conditions such as high blood
pressure, hyperlipidemia, heart infarct, angina, heart failure, stroke, polycystic ovary syndrome
(PCOS), pre-eclampsia, depression, diabetes, bulimia, and anorexia.
Life style factors: Body Mass Index (BMI) was calculated based on women’s weight in kilo-
gram divided by their squared length in meters. Current tobacco use (yes/no), that is, whether
women either smoked cigarettes or used snuff (a typical Swedish tobacco in moist powder
form) was self-reported.
Psychological factors: All participants indicated there experienced level of stress during the
last five years on a four-point Likert-scale ranging from ‘never stressed’ to ‘always stressed’.
They were also asked to indicate whether they have experienced any of the following life stress-
ors during the last five years: a close relative who died; own divorce or separation; a close friend
who died; serious disease or injury; became unemployed; other very stressing event. Moreover,
they reported the average number of hours of sleep per night.
Quality of life. Patient filled out the cancer-specific QoL-questionnaire, the European
Organization for Research and Treatment of Cancer Quality of Life questionnaire Core 30
(EORTC QLQ-C30).[25] It includes global health status and the following five functional scales
(physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue,
nausea or vomiting, and pain), and six single items (dyspnea, insomnia, appetite loss, constipa-
tion, diarrhea, and financial difficulties). These scales are linearly transformed to a scale rang-
ing from 0 to 100. High scores indicate a high level of QoL, functioning or symptomatology.
To reduce the number of tests, we included the most important QoL-domains for healthy
females; the global health status and the five functional scales.[26,27] The EORTC QLQ-C30
has been validated yielding good psychometric properties.[25]
Genotyping. A portion of the KARMA participants was genotyped using the iCOGS chip
as being a part of the iCOGS project (www.nature.com/iCOGS). This chip was specifically
designed to evaluate genetic variants associated with the risk of breast, ovarian and prostate
cancer.[28,29] It consists of 174,574 SNPs, selected in samples from large case-control studies
in disease-based consortia.
A genome-wide imputation of SNPs using the 1000 Genomes Project (1KGP) March 2012
release (updated April 19, 2012) was performed.[30] For the KARMA dataset, the genotypes of
4,310,392 SNPs were successfully called and passed quality control filter (INFO score from
IMPUTE> = 0.8 and minor allele frequency> = 0.01).
Statistical analyses
Relating individual SNPs to quality of life. SNPs were related to each QoL-domain, by
means of regression analyses. We chose to perform principal component analysis to correct for
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PLOS ONE | DOI:10.1371/journal.pone.0140563 October 15, 2015 3 / 11
population stratification as uniform adjustment applied by genomic control may be insufficient
at markers having unusually strong differentiation across ancestral populations and may be
superfluous at markers devoid of such differentiation, leading to a loss in power.[31] The
lambda GC values for each analysis after adjusting for age and an appropriate number of prin-
ciple components ranged from 1.00–1.03, which suggested no remaining evidence of popula-
tion stratification. PCA plots were visually inspected for outliers in terms of ancestry from
CEU (northern and western Europe) clusters. Inspection of the Scree plot showed five principal
components which were included in subsequent analyses. Background characteristics
(Table 1), significantly related (p<0.10) to QoL based on previous analyses in this sample (S1
Table: The association between background characteristics and quality of life using Wald Chi
Square test-statistic), were included as covariables; see Schoormans et al.[23] for a detailed
description. Both partially adjusted (controlling for age and principal components) and fully
adjusted regression analyses (controlling for age, principal components and covariables) were
run. The statistical program PLINK was used to run analyses.[32] Bonferroni correction for
multiple testing was used to define the target p-value of 2.86E-07 (0.05/174,574 SNPs). The dis-
tribution of scores was non-normal for four of the six QoL-domains. Scores on the cognitive
functioning scale were transformed using square root transformation [
p
(101-raw score)]. On
the remaining three domains (i.e. physical functioning; role functioning; and social function-
ing) a large percentage of women (range from 66.6% to 74.5%) reported the maximum score.
These domains were therefore dichotomized; maximum value versus the remaining answers.
Power calculation was done using the pwr.f2.test function in pwr package in R. The degrees
of freedom for the partially and fully adjusted setting were 7 (five PCA’s, age and the outcome
variable) and 13 (adding additional covariates) in the numerator and 5127 and 4681 in the
denominator respectively. The significance level was set to the Bonferroni corrected level and
the effect size was estimated as the fraction between the explained variability reflected by the
coefficient of determination and the unexplained variability as one minus coefficient of deter-
mination from the respective model. Estimated power was 99% and 100% in the partial and
fully adjusted analysis respectively, for an effect size that’s represented with assessing associa-
tion of top variant with the global health/QoL-scale.
Relating the combined effect of SNPs within genes. Gene-based analyses were performed
relating the combined effect of the 174,574 SNPs within each gene to QoL. In total, 16,512 genes
were related to each of the QoL-domains separately, using the Versatile Gene-based Association
Study (VEGAS) software.[33] This software package applies a test by using simulations from the
multivariate normal distribution by incorporating information on a set of SNPs within a gene
while accounting for linkage disequilibrium (LD) between SNPs. VEGAS uses HapMap popula-
tions to estimate patterns of LD.[33] The number of simulations for each gene is determined
adaptively. In the first step, 1000 simulations are run. If the empirical value is<0.01, the number
of simulations are increased to 10,000. If the empirical p-value is<0.001, another 1,000,000 sim-
ulations will be run. The simulations will continue until an empirical p-value of 0 is reached.
Results
Background characteristics and quality of life
In total, for 5,142 healthy women QoL and genotype data was available, hence they were
included in this study. Information on background characteristics and QoL scores are
described in our previous study[23], see Table 1. Mean age was 54 years. The majority of
women had finished gymnasium (32.9%) or university (49.2%). A representative number of
women was on hormone replacement therapy (33%).[34] Almost half of the women (46.6%)
reported to be diagnosed with at least one medical condition. With respect to QoL, KARMA
The Genetic Basis of Quality of Life: A GenomeWide Association Study
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Age in mean years (range)a 54.3 (22–88)
Educational levelb





Being on hormone replacement therapy 1709 (33.2)
Using painkillers 4931 (95.9)





Four or more 68 (1.3)
Lifestyle factors
Body mass index (BMI) as mean score (range)d 25.22 (17–52)
Using tobacco 684 (13.3)
Psychological factors
Stress in the last five yearse
Never stressed 275 (5.4)
Seldom stressed 1849 (36.4)
Often stressed 2379 (46.9)
Always stressed 571 (11.3)





 4 89 (1.7)
Hours of sleepf
5 hours or less 207 (4.4)
6 hours 1103 (23.2)
7 hours 2170 (45.7)
8 hours or more 1269 (26.7)
Quality of life
Global health/ quality of life, mean (SD) 75.8 (22.2)
Functional scales
Physical functioning (highest QoL) 3427 (66.6)
Role functioning (highest QoL) 3825 (74.5)
Emotional functioning, mean (SD) 76.1 (22.8)
Cognitive functioning, mean (SD)g 87.8 (19.2)
(Continued)
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women were representative for the Swedish female population[23]: global health
(mean = 75.8), emotional (mean = 76.1) and cognitive functioning (mean = 87.8). For the
dichotomized scales, the majority of women report the highest score; 66.6% for physical func-
tioning, and 74.5% for role and social functioning scales.
Relating individual SNPs to quality of life
Table 2 shows the results of the association study relating individual SNPs to QoL. In both the
partially adjusted (displayed on the left) and the fully adjusted models (displayed on the right),
none of the SNPs were significantly related to QoL. The strongest association in our data was
observed between physical functioning and rs17814073 (partially adjusted p = 2.06E-06, fully
adjusted p = 1.15E-04).
In-silico functional annotation of the top SNPs and their genes
The in-silico functional annotation of the top SNPs reported in Table 2 was identified. To do
so, we utilized the online databases HaploReg V2 and V3 [www.broadinstitute.org/mammals/
haploreg] to mine ENCODE and RoadMap data; choosing to display results for variants that
are in complete LD (D’ = r2 = 1) with the query SNPs in 1000G Phase 1 European population.
The intronic variant rs813299 is located in 44kb 5' of TRPM1 gene on chromosome 15 and is
predicted to alter affinity of two transcription factor binding sites; with no other variants in
complete LD with it. Variant rs17814073 is located on chromosome 12 at 67kb 5' of CNOT2
gene and is in complete LD with 15 other variants spanning a ~ 51.5 Kb region of which five
were in enhancer regions of several cell lines and DNAse hypersensitive sites; collectively they
alter affinity of numerous transcription factor binding sites. Intronic variant rs2028913 in
LRRTM4 gene was in complete LD with two other variants on chromosome 2 for which one of
the variants, rs765572, altered affinity of ten binding sites and was located in histone enhancer
region in adult liver cell lines. Variant rs811722 located at 185kb 5' of C14orf28 on chromo-
some 14 were predicted to lie in conserved region which is a DNAse hypersensitive site in two
different cell lines; so was the intronic variant rs55513 of NALCN on chromosome 13.
Table 1. (Continued)
N (%)
Social functioning (highest QoL) 3826 (74.5)
Note
a = information is missing for 1 participant
b = information is missing for 14 participants
c = High blood pressure and depression are the most common conditions
d = for 17 participants information was unavailable
e = for 68 participants no information was available
f = information is missing for 393 participants. For global health/quality of life and the functional scales a
higher score indicates a better quality of life. For the continuous variables (i.e. global health/quality of life;
emotional functioning; and cognitive functioning) mean scores (SD) are presented. For the dichotomized
scales (i.e. physical functioning; role functioning; and social functioning) frequencies and percentages for
the category with the highest quality of life is provided. Please note that for the QoL-scales 6, 3, 10, 1, 0, 6
participants respectively information was missing.
g = cognitive functioning was transformed by using square root transformation [
p
(101-raw score)], ranging
from 1–10 with low scores having a better cognitive functioning. The transformed mean score and standard
deviation for cognitive functioning is 2.9 (2.4).
doi:10.1371/journal.pone.0140563.t001
The Genetic Basis of Quality of Life: A GenomeWide Association Study
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Introninc variant of FSTL5 (rs17599095) was in complete LD with four other variants spanning
a region of ~ 11Kb on chromosome 4 for which they altered affinity of different set of tran-
scription binding sites. In addition, the specific function for each gene reported in Table 2 was
identified. The TRPM1 (15q13.3) gene is the founding member of the melastatin-related tran-
sient receptor (TRPM) channel family; contains 29 exons; and is a protein-coding gene that
may play a role in metastasis suppression [UniProtKB(http://www.uniprot.org): Q7Z4N2].
Diseases associated with TRPM1 include melanoma metastasis, and congenital stationary
night blindness, type 1c [http://www.genecards.org]. The CNOT2 (12q15) gene is a protein-
coding gene which is the subunit 2 of CCR4-NOT Transcription Complex which is linked to
various cellular processes including bulk mRNA degradation, miRNA-mediated repression,
translational repression during translational initiation and general transcription regulation
[UniProtKB(http://www.uniprot.org): Q9NZN8]. The LRRTM4 (2p12) gene is a protein-cod-
ing gene that may play a role in the development and maintenance of the vertebrate nervous
system [UniProtKB(http://www.uniprot.org): Q86VH4]. The Chromosome 14 Open Reading
Frame 28 (C14orf28) at 14q21.2 is a protein-coding gene that is uncharacterized [UniProtKB
(http://www.uniprot.org): Q4W4Y0]. The FSTL5 at 4q32.3 is a protein-coding gene which is
an important paralog to the FSTLB1 (3q13.33) gene that may modulate the action of some
growth factors on cell proliferation and differentiation [UniProtKB(http://www.uniprot.org):
Q12841/Q12841].
Relating the combined effect of SNPs within genes
Results of the partially adjusted gene-based tests are provided in Table 3. All associations were
non-significant (bonferroni-corrected p-value = 2.86E-07), p-values ranged from 3.34E-04 for
the association between emotional functioning and TACSTD2 to 1.01E-05 for the relation
between physical functioning and the CNOT2 gene.
Table 2. Relation between quality of life and single nucleotide polymorphisms (n = 174,598).
Partially adjusted Fully adjusted
top SNP Chr Position Minor/ Major MAF Beta(SE) p Beta(SE) p GENE
Quality of life
Global health/ QoL rs813299 15 31438303 A/C 0.31 1.96(0.44) 7.45E-06 1.62(0.40) 5.69E-05 FAM7A1:TRPM1
Functional scales
Physical functioning rs17814073 12 70570216 A/C 0.08 0.41(0.09) 2.06E-06 0.35(0.09) 1.51E-04 CNOT2Ɨ
Role functioning rs2028913 2 77252200 C/G 0.44 -0.19(0.05) 2.25E-05 -0.20(0.05) 5.21E-05 LRRTM4
Emotional functioning rs811722 14 45181337 T/C 0.47 1.91(0.44) 1.22E-05 0.16(0.39) 2.68E-03 C14orf28Ɨ
Cognitive functioninga rs555513 13 101927864 A/G 0.32 0.21(0.05) 3.06E-05 0.19(0.05) 6.99E-05 NALCN
Social functioning rs17599095 4 163007597 T/C 0.10 -0.33(0.07) 7.06E-06 -0.33(0.06) 4.33E-05 FSTL5
Note: In total 174,574 SNPs were available on the imputed iCOGS chip. Bonferroni p-value = 0.05/174,598 = 2.86E-07. For the continuous variables (i.e.
global health/quality of life; emotional functioning; and cognitive functioning) linear regressions were performed. For the dichotomized variables (i.e.
physical functioning; role functioning; and social functioning) we used logistic regression analyses. Chr = chromosome; Position = position of the
chromosome; Minor/major = minor and major alleles based on forward strand and minor allele frequencies in Europeans; MAF = minor allele frequency
over all European controls in iCOGS; Beta = beta value for the minor allele relative to the major allele; SE = standard error; p = p-value.
a = cognitive functioning was transformed by using square root transformation [
p
(101-raw score)] ranging from 1–10, with low scores having a better
cognitive functioning, therefore the direction of the relation is reversed.
Ɨ = the gene to which this SNP belongs is unknown, the closest gene is reported.
doi:10.1371/journal.pone.0140563.t002
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Discussion
No statistically significant associations between genetic variations (individual SNPs and com-
bined effects of SNPs within genes) and QoL were found in the present study. There are various
reasonable grounds for the absence of associations in our sample. First, it is plausible that the
null findings result–at least in part–from the limitations inherent to our study. Due to our
healthy female sample there was little variation in QoL scores. In addition, the dispersion over
the entire genome may be skewed, since genotyping was performed by using the imputed
iCOGS chip, which was originally built to identify the genetic risk for breast, ovarian and pros-
tate cancer. Furthermore, other factors that were not measured could also impact variation in
QoL, either directly or via genes. A detailed description of these plausible relations are pre-
sented in the adapted model developed by Wilson and Cleary provides.[9] In particular, associ-
ations between QoL and genes may depend on the environmental context (geneenvironment
interactions) which differs across populations.[35] Finally, it is important to note, that this
GWAS was performed in a single study. To the best of our knowledge no independent datasets
are available in which both genetic and QoL-information is available. Hence, validation was
not optional. Given the continuously developing field, we believe that the number of studies
will increase in the near future enabling validation of our findings. We would also like to
address strengths of this study. This is the first GWAS which relates QoL to genes using a large
sample of healthy females. As we control for background characteristics including self-reported
chronic morbidities, we minimize the impact of illnesses. Moreover, although factors known to
impact QoL (e.g. mood) are not measured, the large sample ensures us that effects of these fac-
tors on QoL are cancelled out. Furthermore, the included sample of healthy women is repre-
sentative for the general Swedish population in terms of QoL, increasing generalizability of the
results.
Whereas we did not find evidence for a genetic predisposition for QoL, it is likely that some
variation in QoL is the result of alterations in various genes that impact one or more biological
pathways, rather than the effect of single SNPs or genes. In related fields, such as psychiatric
genetics, there is an abundance of studies demonstrating small effect sizes for individual genes,
[10] which are difficult to replicate[36]. These individual SNP association analyses evaluate the
significance of individual SNPs and offer therefore limited understanding of the complex phe-
notype. For future GWAS we therefore propose a system biology approach, considering not
only SNPs and genes, but also pathways. A pathway-based or system biology approach is a
complementary and powerful approach to analyze the combined effect of genes and their bio-
logical implications.[37,38] This strategy could also be useful in unraveling pathways that
include information on gene functions and molecular mechanisms that are involved in QoL.
Table 3. Gene-based test for the single nucleotide polymorphisms.
Quality of life Chr Gene nSNPs Start pos End pos p-value
Global health/ QoL 12 WNT5B 26 1596482 1626639 1.94E-04
Functional scales
Physical functioning 12 CNOT2 13 68923043 69035040 1.10E-05
Role functioning 6 WRNIP1 13 2710664 2730978 1.35E-04
Emotional functioning 1 TACSTD2 10 58813682 58815754 3.34E-04
Cognitive functioning 18 ST8SIA5 10 42513078 42591037 2.65E-04
Social functioning 4 FSTL5 24 162524498 163304636 9.50E-05
Note: Bonferroni corrected p-value of 3.03E-06 (0.05/16512 genes). Chr = Chromosome; nSNPs = number of SNPs; test stat = test statistic.
doi:10.1371/journal.pone.0140563.t003
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With this new approach three important steps need to be taken. First, pathways that could be
related to QoL should be identified. Second, genes for each pathway need to be determined.
Genes with similar functions interact with each other more closely in the protein-protein inter-
action (PPI) networks than functionally unrelated genes.[39] Likewise, phenotypes are often
caused by interacting functionally related genes.[37] Third, the actual statistical testing needs
to be based on new methods were SNP effects are combined to represent gene effects in which
subsequently they are combined into pathways. One technique is to combine p-values of all
SNPs within a gene into one single p-value, which is similar to our approach using VEGAS,
and then combine the p-values of all genes within one pathway to test the overall association
between a pathway and QoL.[40,41] Although inspiring and hopeful, there are obvious limita-
tions to this approach. Currently, several possible biological pathways have been suggested to
be involved in QoL.[42] The selection of these pathways was formulated based on known rela-
tions between genes and QoL-domains, such as pain and fatigue. The identified biological
pathways can therefore be seen as a candidate genetic-pathway approach. On a GWAS level
however, the literature on epigenetic QoL-research is still in its infancy. Hence, this research
field is currently too immature to formulate meaningful pathways. Moreover, pathway analysis
relies on the accuracy and completeness of pathway annotation databases, such as KEGG, Bio-
Carta, and the human interactome. That said, pathway-based analyses remain essential to gain
in-depth knowledge of molecular mechanisms of QoL. In conclusion, in the current study we
did not find evidence for a relation between genes and QoL. Further research is needed, as
genetic markers of QoL will be valuable in clinical settings. Identification of persons susceptible
to impairments in their QoL can be done by means of indicator genes and pathways. This is
especially insightful when assisting persons under duress, for example when patients are being
treated for a life threatening illness. When choosing treatments, clinicians may be guided by
this information, opting for minimally invasive treatments when it comes to QoL and provid-
ing additional support to those patients who need it. Furthermore, by understanding the bio-
logical mechanisms underlying poor QoL, improvements may be feasible by interventions at a
molecular level.
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